Figure 7.

Downregulation of LINC01116 Reduces the In Vivo Sensitivity of PC9/R Cells to Gefitinib and the Expression of LINC01116 in LA Tissues Was Negatively Correlated with IFI44

Mice were treated with gefitinib (10.0 mg/kg) or with 1% Tween 80. (A) Representative features of tumors 18 days after inoculation using PC9/R/sh-LINC01116 or PC9/R/Empty vector cells treated with 1% Tween 80 or gefitinib. (B and C) Tumor volume and weight at day 18 after the inoculation. (D) Quantitative real-time PCR detection of relative LINC01116 expression in tumors developed from PC9/R/shRNA-LINC01116 or PC9/R/Empty vector cells treated with 1% Tween 80 or gefitinib. (E) Western blotting detection of IFI44 protein expression in tumors developed from PC9/R/shRNA-LINC01116 or PC9/R/Empty vector cells treated with 1% Tween 80 or gefitinib. (F) Immunostaining of IFI44 and ki-67 protein expression in tumors developed from PC9/R/shRNA-LINC01116 or PC9/R/Empty vector cells treated with 1% Tween 80 or gefitinib. Upper, H&E staining. Intermediate and lower, immunostaining. Bars, 100 μm. (G) quantitative real-time PCR detection of relative LINC01116 expression in responding (n = 11) and non-responding (n = 14) LA tissues (p < 0.0001). Abundance of LINC01116 was normalized to U6 RNA. (H) quantitative real-time PCR detection of relative IFI44 mRNA expression in responding (n = 11) and non-responding (n = 14) LA tissues (p < 0.0001). Abundance of IFI44 was normalized to GAPDH. (I) A statistically significant inverse correlation between LINC01116 and IFI44 mRNA levels in 25 cases of LA tissues (Pearson’s correlation analysis, R = −07112; p < 0.0001). Data are expressed as the mean ± SD of three individual experiments. *p < 0.05; **p < 0.01.